D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
AssigneesDrexel University, Rutgers, The State University of New Jersey
InventorsSandhya Kortagere, Eldo V. Kuzhikandahil
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
Claims11
A method of treating or ameliorating levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, the method comprising administering to the patient a therapeutically effective amount of at least one compound selected from the group consisting of:
- a compound of formula (IIa) or (IIb):
- wherein in formula (IIa) or (IIb):
- R1 is independently selected from the group consisting of H, cyano halogen, C1-C6 alkoxy, nitro, and C1-C6 alkyl;
- R2 is independently selected from the group consisting of cyano, halogen, C1-C6 alkoxy, nitro, and C1-C6 alkyl;
- R3 and R4 are independently selected from the group consisting of H and methyl;
- R5 is selected from the group consisting of H and C1-C6 alkyl;
- and,
- m is 1;
- 2,7-diamino-5-(4-fluorophenyl)-4-oxo-3,4,5,6-tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile;
- (Z)-2-(1H-benzo[d]imidazol-2-yl)-N′-hydroxy-3-(4-methoxyphenyl)propanimidamide;
- or a salt thereof, or any mixtures thereof.
A method of treating and ameliorating Parkinson's Disease in a patient, the method comprising administering to the patient a therapeutically effective amount of at least one compound selected from the group consisting of:
- a compound of formula (IIa) or (IIb):
- wherein in formula (IIa) or (IIb):
- R1 is independently selected from the group consisting of H, cyano halogen, C1-C6 alkoxy, nitro, and C1-C6 alkyl;
- R2 is independently selected from the group consisting of cyano, halogen, C1-C6 alkoxy, nitro, and C1-C6 alkyl;
- R3 and R4 are independently selected from the group consisting of H and methyl;
- R5 is selected from the group consisting of H and C1-C6 alkyl;
- and,
- m is 1;
- 2,7-diamino-5-(4-fluorophenyl)-4-oxo-3,4,5,6-tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile;
- (Z)-2-(1H-benzo[d]imidazol-2-yl)-N′-hydroxy-3-(4-methoxyphenyl)propanimidamide;
- or a thereof, or any mixtures thereof.
Dependencies are inferred from the claim text.